Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Huntington disease
Biotech
VectorY raises $138M to push forward ALS program
VectorY Therapeutics has secured $138 million in a series A financing that will help the Dutch biotech advance its preclinical lead program in ALS.
Gabrielle Masson
Nov 13, 2023 10:26am
JPM23: Annexon looks for '2 ways to win' in Huntington's trial
Jan 11, 2023 12:55pm
AbbVie, Ipsen exit R&D deals to cap off lousy year for Exicure
Dec 14, 2022 7:15am
UniQure set to resume dosing in open-label Huntington's trial
Nov 2, 2022 10:18am
3 patients hospitalized in uniQure Huntington's disease trial
Aug 8, 2022 11:45am
Will Annexon's Huntington's data smooth over worried investors?
Jun 7, 2022 6:30am